Industry News
QRxPharma hits on right dose
QRxPharma completes Phase III dose pilot for opioids [ + ]
Progen targets epigenetics
Progen working on polyamine analogues for DNA demethylases, cell proliferation [ + ]
Virionyx goes Innate
NZ company changes name, repositions strategy [ + ]
Fight of the honeybees
Spanish researchers may have found a cure for honeybee colony collapse disorder [ + ]
Australian biotech market today 15.04.09
Acrux, Atcor, Cellestis, Pharmaxis, Mesoblast, Circadian, Alchemia [ + ]
Ovature trial cut short
Novogen’s Marshall Edwards subsidiary to wind up ovarian cancer trial early [ + ]
Acuvax cashes in RESprotect
Acuvax divests small holding in German developer of pancreatic cancer drug [ + ]
Antarctic Ice Bridge Due to Collapse Within Days
Massive ice shelf withinin days of being separated from the Antarctic mainland. [ + ]
Australian biotech market today 14.04.09
Cellestis, ChemGenex, Mesoblast, Pharmaxis, Novogen, Probiotec, LabTech Systems [ + ]
Canadian swine for Stirling
Stirling Products signs Canadian research agreement for R-salbutamol [ + ]
Genes, environment and ADHD
QBI researchers are trying to find genetic links to ADHD in 600-family study [ + ]
Australian biotech market today 09.04.09
Genera Biosystems, ChemGenex, Pharmaxis, LCT, pSivida, Bionomics, Mesoblast [ + ]
Q&A with Kim Carr
Senator Kim Carr on the Innovation White Paper, Commercial Ready and the GFC [ + ]
What the government is doing for biotech
In advance of the 2009 BIO convention in Atlanta, Senator Kim Carr writes the foreword to the March/April issue of Australian Life Scientist. [ + ]
